US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% SNDK $1,719.99 ▲+0.00% NVDA $233.95 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% WDC $415.29 ▲+0.00% MSTR $160.01 ▲+0.00%
FinancialContent

Articles published by CEL-SCI Corporation

< Previous 1 2 3 Next >
News headline image
CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI’s Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Announces Closing of $2.5 Million Offering
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Announces Pricing of $2.5 Million Offering
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Announces Closing of $5 Million Offering
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Announces Pricing of $5 Million Public Offering
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Announces Proposed Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Announces Closing of $10.8 Million Offering
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Announces Pricing of $10.8 Million Offering
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Appoints Robert Watson as Chairperson of the Board
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
News headline image
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
< Previous 1 2 3 Next >